General Inflammation Testing (CRP and ESR) Reimbursement
This BCBSNM clinical payment and coding policy (CPCPLABO49) governs reimbursement criteria for measurement of erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) across BCBSNM products; providers and claims administrators should follow plan documents and provider contracts for coverage determination.
New policy
Reimbursement Criteria for ESR and CRP
ESR/CRP reimbursement criteria
Covered when the following specific conditions are met:
ALL of the following
ONE of
- One measurement of erythrocyte sedimentation rate (ESR) for patients with Hodgkin Lymphoma may be reimbursable.
Medical record documentation of Hodgkin Lymphoma diagnosis should be available.
- Measurement of either C‑Reactive Protein (CRP) or ESR for the diagnosis, assessment, or monitoring of inflammatory disorders, undiagnosed conditions, or to detect acute phase inflammation may be reimbursable.
Clinical indication supporting inflammatory disorder or undiagnosed condition should be documented.
Concurrent testing
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.